Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Biodefense BAA Supports Adjuvant Development for Emerging Diseases

by Global Biodefense Staff
August 16, 2012

The National Institute of Allergy and Infectious Diseases (NIAID), Division of Allergy, Immunology and Transplantation is renewing a Broad Agency Announcement (BAA) in support of the Adjuvant Development Program to advance novel vaccine adjuvants towards licensure for human use.

NIAID supports extramural research to develop new products to protect the public from the health consequences of biological agents that might be used in acts of bioterrorism and from emerging and re-emerging diseases, such as West Nile Virus, multi-drug resistant Tuberculosis and Dengue Fever.

The biological agents deemed to pose the greatest threat to civilian populations are prioritized in the NIAID Emerging and Re-emerging Infectious Diseases list. NIAID also contributes to meeting the goals for host defense described in the NIAID Strategic Plan for Biodefense (.pdf) by supporting the development of new vaccine adjuvants that stimulate stronger, more protective immune response.

This BAA supports the development of adjuvants through immunological characterization studies and lead compound optimization.  Candidate vaccine adjuvants eligible for support must have already been identified as minimally reactogenic and characterized as safe after administration in an animal model; have documented evidence that demonstrates a mechanism of action for the adjuvant; been shown to safely augment the ability of a vaccine to protect against pathogen challenge in an in vivo animal model; and shown that the adjuvant has immune-enhancing activity with human primary cells or tissues.

Technical proposals should demonstrate in a Product Development Plan how funding will significantly advance the development of candidate vaccine adjuvants within a maximum five year period of contract performance.

It is anticipated that the government will award multiple cost reimbursement, completion type contracts with options, beginning on or about August 30, 2013.

All responsible sources may submit a proposal which shall be considered by the Agency.   This BAA will be posted under Solicitation Number: BAA-NIAID-DAIT-NIH-AI-2012146 on FedBizOpps.gov on or about August 17, 2012.

Tags: Animal ModelsBAABioterrorismDengueEmerging ThreatsVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC